Compare IQ & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQ | WVE |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | China | Singapore |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | 2015 |
| Metric | IQ | WVE |
|---|---|---|
| Price | $1.23 | $5.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $2.91 | ★ $29.81 |
| AVG Volume (30 Days) | ★ 6.7M | 3.1M |
| Earning Date | 05-18-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $3.54 | $85.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $0.95 | $5.02 |
| 52 Week High | $2.76 | $21.73 |
| Indicator | IQ | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 40.70 |
| Support Level | $1.20 | $5.48 |
| Resistance Level | $1.26 | $6.48 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 89.58 | 13.92 |
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.